|Year : 2013 | Volume
| Issue : 2 | Page : 60-64
The effects of unripe grape extract on systemic blood pressure, nitric oxide production, and response to angiotensin II administration
Mehdi Nematbakhsh1, Behzad Zolfaghari2, Fatemeh Eshraghi3, Tahereh Safari4, Zahra Pezeshki3, Seyyed Mohammad-Ali Sorooshzadeh3
1 Water and Electrolytes Research Center; Department of Physiology; Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Pharmacognosy, Isfahan University of Medical Sciences, Isfahan, Iran
3 Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Water and Electrolytes Research Center; Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
|Date of Submission||29-Aug-2012|
|Date of Decision||29-Dec-2012|
|Date of Web Publication||15-Apr-2013|
Water and Electrolytes Research Center, Kidney Diseases Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan
Source of Support: This research was supported by Isfahan University of Medical Sciences (grant # 289020),, Conflict of Interest: None
| Abstract|| |
Background: Hypertension is the most common disease in the world. In Iranian folk medicine, unripe grape juice has been used as antihypertention remedy, but no data is documented for this popular belief. This study was designed to determine the effect of unripe grape extract (UGE) on blood pressure and the response to angiotensin II in rat. Materials and Methods: Unripe grape was collected, air dried, and extracted and concentrated. Four groups of Wistar rats received single doses of 125, 250, and 500 mg/kg of UGE or saline, respectively. The direct blood pressure and the serum nitrite level were measured one hour post UGE administration. The animals also were subjected to the infusion of various angiotensin II concentrations (100, 300, and 1000 μg/kg/min), and blood pressure was determined. Results: Mean arterial, systolic, and diastolic pressures (MAP, SP, and DP) in all UGE treated groups were less than the control group, but only at the dose of 125 mg/kg (Group 1) they were significantly different ( P < 0.05). The level of nitrite in groups 1-3 were significantly greater than the control group ( P < 0.05). No significant differences were detected for the MAP, SP, and DP to different concentrations of angiotensin II among these groups. Conclusion: UGE potentially attenuate MAP, SP, and DP via vasodilatation induced by nitric oxide production.
Keywords: Angiotensin II, blood pressure, nitric oxide, unripe grape extract, VitisVinifera
|How to cite this article:|
Nematbakhsh M, Zolfaghari B, Eshraghi F, Safari T, Pezeshki Z, Sorooshzadeh SM. The effects of unripe grape extract on systemic blood pressure, nitric oxide production, and response to angiotensin II administration. Phcog Res 2013;5:60-4
|How to cite this URL:|
Nematbakhsh M, Zolfaghari B, Eshraghi F, Safari T, Pezeshki Z, Sorooshzadeh SM. The effects of unripe grape extract on systemic blood pressure, nitric oxide production, and response to angiotensin II administration. Phcog Res [serial online] 2013 [cited 2019 May 25];5:60-4. Available from: http://www.phcogres.com/text.asp?2013/5/2/60/110511
| Introduction|| |
Hypertension is the most common disease in the world. Due to obesity and the change of lifestyle, the incidence of hypertension has increased mostly in the developed countries. ,,,, The prevalence of hypertension varies worldwide depending on the age, race, gender, and risk factors. ,,, Accordingly, new strategies and treatment procedures have been developed to control the blood pressure in general population. In contrast, natural products also have been considered as a potential medication to control blood pressure. The land of Persia has scientific and historical background to use plants as drugs in medical treatment. In Iranian folk medicine it is believed that unripe grape (scientifically named VitisVinifera) juice could control hypertension. Unripe grape juice also is called "verjuice", which is much like vinegar. In other words, those grapes do not ripen up, they are getting juiced. In Persian language unripe grape is named "Ghureh" and as fresh, juice or dried has been widely used as a flavoring agent in many Iranian dishes and salads. Additionally it has been used as antigout and antiobesity in Iranian traditional medicine.  Unripe grape is rich in antioxidant of polyphenolic compounds. ,,,,, The protective role of grape seeds in cardiovascular system is reported, ,,,,,,,,, and these effects are related to the existence of polyphenolic compounds in the grape. ,, The role of unripe grape on blood pressure is not well documented yet. If we accept the population hypothesis, unripe grape may affect vascular system to promote vascular dilatation, or it may have inhibitory effect on rennin angiotensin system. Accordingly, we hypothesized that unripe grape may potentially promote nitric oxide (NO) production or limit the response to angiotensin II administration. In order to test this hypothesis, we measured blood pressure one hour post unripe grape extract (UGE) administration, and the response of blood pressure to graded angiotensin II infusion also was determined in a rat model.
| Materials and Methods|| |
The unripe grape (Shiraz, Iran variety) was obtained from a local market in Shiraz, Iran in July 2010. The unripe grape was grounded by a mixture to obtain juice. The unripe grape was air-dried under a controlled temperature (22°C). The plant material (450 g dry weight) was powdered and then exhaustively extracted according to percolation procedurewith EthOH/H 2 O (70:30), then filtered and dried in freeze dryer, to obtain dried powder (90 g).
Total phenolic contents estimation
Total phenolic contents of UGE were estimated according to the method described by Singleton et al.  Twenty microliters of the 0.85% extract was added to 1.58 mL water, and then100 μL of the Folin-Ciocalteu reagent was added, and mixed. After 30 seconds, 300 μL of 20% Na 2 CO 3 was added and thoroughly mixed and reminded in 20°C for 2 hours. Absorbance was measured at 765 nm. Standard curve of absorbance was created versus concentration of gallic acid (50-500 μg) and total phenolic contents were reported as percentage equivalents to gallic acid.
Adult male (212 ± 4 g) Wistar rats (Animal Centre, Ahvaz University of Medical Sciences, Ahvaz, Iran) were used for this research. The rats were individually housed at a temperature of 23-25°C. Rats had free access to water and chow. The rats were acclimatized to this diet for at least one week prior to experiment. The experimental procedures were approved in advance by the Isfahan University Medical Sciences Ethics Committee.
Four groups of rats were randomly assigned. Group 1-3 received a single doses of UGE; 125 (Group 1), 250 (Group 2), or 500 (Group 3) mg/kg, ip, respectively. The control group (Group 4) received saline in equal volume. Thirty minute later, the animals were anesthetized (Inactin; thiobutabarbital, 150 mg/kgi.p.; Sigma, St Louis, MO, U.S.A.) and trachea was isolated to insert air ventilation tube. Catheters were implanted into the jugular vein and carotid artery. Catheterization time was about 15 minutes for each animal. The animals with catheterization times more than 15 minutes were omitted from the study. The direct blood pressure was measured continuously, and after 15 minutes of equilibrium time (exactly one hour post UGE administration) the blood pressures were recorded, and blood samples were obtained. The data at this time was considered as one hour post UGE administration. Then a series of intravenous (via jugular vein) infusions of Ang II (100, 300, and 1000 ng/kg/min) were commenced. Each dose was administered until stability for arterial blood pressure was achieved (about 10 minutes period), and then the data was collected for about 5 minutes.
The level of serum nitrite was determined one hour after UGE administration. The serum level of nitrite (stable NO metabolite) was measured using a colorimetric assay kit (Promega Corporation, USA) that involves the Griess reaction. Briefly, after adding sulphanilamide solution and incubation, N-1-naphtylethylenediamine dihydrochloride solution was added. Then, absorbance was measured by a microreader in 540 nm wavelength. The nitrite concentration of samples was determined by comparison to nitrite standard reference curve.
Data are expressed as mean ± SEM. To compare the trend of blood pressure response to graded angiotensin II infusion between the groups, repeated measured analysis was applied. Unpaired t-tests also was applied to compare the blood pressure between the experimental groups. Values of P < 0.05 were considered statistically significant.
| Results|| |
The total phenolic content of UGE was estimated as 8.5%gallic acid equivalents.
The effect of UGE on blood pressure
The data obtained for mean arterial, systolic, and diastolic pressures (MAP, SP, and DP) are shown in [Figure 1]. In all UGE treated groups, MAP, SP, and DP were less than the control group, but only they were significant at the dose of 125 mg/kg (Group 1)( P < 0.05). Mean heart rates in groups 1-4 were recorded as 286 ± 12, 300 ± 20, 358 ± 12, and 341 ± 24/minute, respectively. The statistical analysis indicated that one hour post UGE administration, the heart rate in group 1 was significantly different from the control group ( P < 0.05). UGE increased the serum nitrite level in groups 1-3 significantly when compared with the control group ( P < 0.05) [Figure 1].
|Figure 1: Mean arterial, systolic, and diastolic pressures (MAP, SP, and DP) and nitric oxide (nitrite) levels in four experimental groups. The groups 1-4 stand for animals treated with 125, 250, and 500 mg/kg of unripegrape extract (UGE) and placebo (control), respectively. Data are presented as mean ± SEM and were analyzed using unpaired t-test|
Click here to view
Blood pressure response to graded angiotensin II infusion
The data obtained for blood pressure one hour post UGE was considered as base for angiotensin II infusion, and since these data were not statistically the same in all groups, therefore instead of using absolute data for blood pressure in response to angitensin II infusion, we used the percentage change in blood pressures. Angiotensin II infusion increased MAP, SP, and DP in all experimental groups (P < 0.05). However, statistical analysis for percentage change of blood pressures indicated no significant difference between the groups [Figure 2]. This analysis indicated that UGE did not limit angiotensin II effects.
|Figure 2: The percentage change of mean arterial, systolic, and diastolic pressures (MAP, SP, and DP) response to graded angiotensin II infusion in four experimental groups. The groups 1-4 stand for animals treated with 125, 250, and 500 mg/kg of unripe grape extract (UGE) and placebo (control), respectively. Data are presented as mean ± SEM and were analyzed using a repeated-measures ANOVA (for percentage change of MAP, SP, and DP from angiotensin II 0-1000 ng/kg/min), using the factors treatment; UGE or placebo and angiotensin administration (PTreat), Ang II (PAng), and the interaction between treatment and angiotensin II (PAng Treat)|
Click here to view
| Discussion|| |
The effects of UGE on MAP, SP, DP, and nitrite level were the main objectives of this study. The blood pressures response to graded angiotensin II infusion also was determined. One hour post UGE administration, the blood pressure in the first group (UGE: 125 mg/kg) was reduced significantly. This reduction was assumed to be related to the level of nitrite or NO. UGE contains polyphenolic compounds, ,, and activation of endothelial NO synthase by polyphenols has been reported.  NO act as a vasodilator via different mechanisms, and it plays a pivotal role in endothelial function. ,,,,,, Our findings for the first time support the idea that UGE administration stimulates NO production and promotes systemic vasodilatation. Another interpretation for this result is related to antioxidant role of unripe grape, , which may preserve endothelium-dependent vasodilatation. 
UGE did not affect blood pressure response to graded angiotensin II. We hypothesized that reduction of blood pressure by UGE may occur through inhibition of RAS activities either by an effect on angiotensin converting enzyme (ACE) or angiotensin II receptors (AT1 or AT2). However, our findings reject this hypothesis. The antioxidant effect of ACE has been reported,  and administration of angiotensin II decreases renal antioxidant enzyme activities.  The ATI antagonist; losartan, also has antioxidant effect. ,,, It seems the antioxidant effect of unripe grape potentially had no effects on RAS or its receptors.
| References|| |
|1.||Dong G, Sun Z, Zheng L, Li J, Zhang X, Xu C, et al. Prevalence, awareness, treatment, and control of hypertension in rural adults from Liaoning Province, northeast China. Hypertens Res 2007;30:951-8. |
|2.||Dong GH, Sun ZQ, Zhang XZ, Li JJ, Zheng LQ, Li J, et al. Prevalence, awareness, treatment and control of hypertension in rural Liaoning province, China. Indian J Med Res 2008;128:122-7. |
|3.||Mbanya JC, Minkoulou EM, Salah JN, Balkau B. The prevalence of hypertension in rural and urban Cameroon. Int J Epidemiol 1998;27:181-5. |
|4.||Mohammadi E, Abedi HA, Gofranipour F, Jalali F. Partnership caring: A theory of high blood pressure control in Iranian hypertensives. Int J Nurs Pract 2002;8:324-9. |
|5.||Unwin N, Setel P, Rashid S, Mugusi F, Mbanya JC, Kitange H, et al. Noncommunicable diseases in sub-Saharan Africa: Where do they feature in the health research agenda? Bull World Health Organ 2001;79:947-53. |
|6.||Ordunez P, Silva LC, Rodriguez MP, Robles S. Prevalence estimates for hypertension in Latin America and the Caribbean: Are they useful for surveillance? Rev Panam Salud Publica 2001;10:226-31. |
|7.||Oh JY, Hong YS, Sung YA, Barrett-Connor E. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care 2004;27:2027-32. |
|8.||Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9. |
|9.||Jazaeri G. Language of foods. Tehran, Iran: Amir Kabir Publication; 1980. |
|10.||Kaliora AC, Kountouri AM, Karathanos VT. Antioxidant properties of raisins (Vitis vinifera L.). J Med Food 2009;12:1302-9. |
|11.||Kedage VV, Tilak JC, Dixit GB, Devasagayam TP, Mhatre M. A study of antioxidant properties of some varieties of grapes (Vitis vinifera L.). Crit Rev Food Sci Nutr 2007;47:175-85. |
|12.||Orhan N, Aslan M, Orhan DD, Ergun F, Yesilada E. In-vivo assessment of antidiabetic and antioxidant activities of grapevine leaves (Vitis vinifera) in diabetic rats. J Ethnopharmacol 2006;108:280-6. |
|13.||Janisch KM, Olschlager C, Treutter D, Elstner EF. Simulated digestion of Vitis vinifera seed powder: Polyphenolic content and antioxidant properties. J Agric Food Chem 2006;54:4839-48. |
|14.||Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B. Commercial dietary ingredients from Vitis vinifera L. leaves and grape skins: Antioxidant and chemical characterization. J Agric Food Chem 2006;54:319-27. |
|15.||Braidot E, Zancani M, Petrussa E, Peresson C, Bertolini A, Patui S, et al. Transport and accumulation of flavonoids in grapevine (Vitis vinifera L.). Plant Signal Behav 2008;3:626-32. |
|16.||Yamakoshi J, Kataoka S, Koga T, Ariga T. Proanthocyanidin-rich extract from grape seeds attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1999;142:139-49. |
|17.||Karthikeyan K, Bai BR, Devaraj SN. Efficacy of grape seed proanthocyanidins on cardioprotection during isoproterenol-induced myocardial injury in rats. J Cardiovasc Pharmacol 2009;53:109-15. |
|18.||Karthikeyan K, Bai BR, Devaraj SN. Efficacy of grape seed proanthocyanidins on serum and heart tissue lipids in rats subjected to isoproterenol-induced myocardial injury. Vascul Pharmacol 2007;47:295-301. |
|19.||Karthikeyan K, Bai BR, Devaraj SN. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int J Cardiol 2007;115:326-33. |
|20.||Demirkaya E, Avci A, Kesik V, Karslioglu Y, Oztas E, Kismet E, et al. Cardioprotective roles of aged garlic extract, grape seed proanthocyanidin, and hazelnut on doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 2009;87:633-40. |
|21.||Leifert WR, Abeywardena MY. Cardioprotective actions of grape polyphenols. Nutr Res 2008;28:729-37. |
|22.||Cheng M, Gao HQ, Xu L, Li BY, Zhang H, Li XH. Cardioprotective effects of grape seed proanthocyanidins extracts in streptozocin induced diabetic rats. J Cardiovasc Pharmacol 2007;50:503-9. |
|23.||Chang WT, Shao ZH, Vanden Hoek TL, McEntee E, Mehendale SR, Li J, et al. Cardioprotective effects of grape seed proanthocyanidins, baicalin and wogonin: Comparison between acute and chronic treatments. Am J Chin Med 2006;34:363-5. |
|24.||Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, et al. Grape polyphenols exert a cardioprotective effect in pre- and post menopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 2005;135:1911-7. |
|25.||Sato M, Maulik G, Ray PS, Bagchi D, Das DK. Cardioprotective effects of grape seed proanthocyanidin against ischemic reperfusion injury. J Mol Cell Cardiol 1999;31:1289-97. |
|26.||Lanningham-Foster L, Chen C, Chance DS, Loo G. Grape extract inhibits lipid peroxidation of human low density lipoprotein. Biol Pharm Bull 1995;18:1347-51. |
|27.||Singleton VL, Orthofer R, Lamuela-Raventós RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent. Methods Enzymol 1999;299:152-78. |
|28.||Rathel TR, Samtleben R, Vollmar AM, Dirsch VM. Activation of endothelial nitric oxide synthase by red wine polyphenols: Impact of grape cultivars, growing area and the vinification process. J Hypertens 2007;25:541-9. |
|29.||Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: Role of bradykinin and nitric oxide. J Hypertens Suppl 2006;24:S39-43. |
|30.||Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: Role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 2005;3:133-48. |
|31.||Higashi Y, Yoshizumi M. Exercise and endothelial function: Role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients. Pharmacol Ther 2004;102:87-96. |
|32.||Andreassen AK, Kirkeboen KA. Endothelial function in coronary atherosclerosis and heart failure: The role of nitric oxide in regulation of vasomotor tone. Tidsskr Nor Laegeforen 1999;119:4066-9. |
|33.||Paravicini TM, Miller AA, Drummond GR, Sobey CG. Flow-induced cerebral vasodilatation in vivo involves activation of phosphatidylinositol-3 kinase, NADPH-oxidase, and nitric oxide synthase. J Cereb Blood Flow Metab 2006;26:836-45. |
|34.||Varin R, Mulder P, Richard V, Tamion F, Devaux C, Henry JP, et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation 1999;99:2951-7. |
|35.||Persson MG, Wiklund NP, Gustafsson LE. Nitric oxide requirement for vasomotor nerve-induced vasodilatation and modulation of resting blood flow in muscle microcirculation. Acta Physiol Scand 1991;141:49-56. |
|36.||Schwarzacher SP, Hutchison S, Chou TM, Sun YP, Zhu BQ, Chatterjee K, et al. Antioxidant diet preserves endothelium-dependent vasodilatation in resistance arteries of hypercholesterolemic rabbits exposed to environmental tobacco smoke. J Cardiovasc Pharmacol 1998;31:649-53. |
|37.||Benzie IF, Tomlinson B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br J Clin Pharmacol 1998;45:168-9. |
|38.||De Craemer D, Lobe E, Pauwels M, Verbeelen D, Van den Branden C. Angiotensin II administration causes enhanced expression of glomerulosclerosis-related markers and decreased renal antioxidant enzyme activities in rats. Exp Nephrol 2001;9:125-32. |
|39.||Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl Res2010;156:26-36. |
|40.||Garcia G, Rodriguez-Puyol M, Alajarin R, Serrano I, Sanchez-Alonso P, Griera M, et al. Losartan-antioxidant hybrids: Novel molecules for the prevention of hypertension-induced cardiovascular damage. J Med Chem 2009;52:7220-7. |
|41.||Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007;30:1119-28. |
|42.||Liptakova A, Ulicna O, Durackova Z, Bozek P, Vancova O. Effect of losartan on antioxidant status in rats with diabetes mellitus. Ceska Slov Farm 2001;50:193-6. |
[Figure 1], [Figure 2]